GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Gilead Sciences Inc (MEX:GILD) » Definitions » Price-to-Funds-From-Operations

Gilead Sciences (MEX:GILD) Price-to-Funds-From-Operations : (As of Apr. 12, 2025)


View and export this data going back to 2008. Start your Free Trial

What is Gilead Sciences Price-to-Funds-From-Operations?

Price-to-Funds-From-Operations only applies to REITs.


Gilead Sciences Business Description

Address
333 Lakeside Drive, Foster City, CA, USA, 94404
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).